TNF and neoplasm: In this regard, targeting of TNFα to tumor neo-vasculature by conjugation with a CNGRC peptide that binds the CD13 aminopeptidase N [127] revealed a strong anti-tumor efficacy in several preclinical models [128], and it is being evaluated in clinical trials in melanoma and other solid tumors [129,130].